Cardax, Inc. (CDXI)

0.0000 0.0000 (0.00%) At close: 10:38AM EDT

Cardax, Inc.

2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822
United States
808 457 1400
https://www.cardaxpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David G. Watumull	Chairman & CEO	214.96k	N/A	1950
Mr. David M. Watumull	COO & CFO	162.11k	N/A	1982
Mr. Gilbert Shin	Vice President of Retail Sales & Marketing	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

Corporate governance

Cardax, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.